Supreme Court Cancer Drug Overpricing Hearing
Analysis based on 9 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The hearing signals heightened judicial scrutiny of pharmaceutical pricing and distribution margins in India, raising regulatory risk for drugmakers and retailers that rely on high MRP-to-PTR spreads on essential medicines. Any eventual cap on MRP or stricter enforcement of the Drugs (Prices Control) Order could compress margins in the domestic pharma supply chain, though no immediate financial or operational impact has materialized.
The India — Supreme Court of India on September 22, 2026 heard two public interest petitions concerning drug pricing and prescription practices. A bench of Justices Vikram Nath and Sandeep Mehta expressed shock that an essential cancer medicine carried a printed maximum retail price of Rs 27,000 while its price to retailer was only Rs 2,700, calling the tenfold markup a broad daylight dacoity, extortion, rampage and carnage against patients. The court questioned why authorities responsible for price control remained silent and asked why MRP could not be capped at a percentage above cost rather than left unlimited. Justice Mehta noted that many patients are treated under India — Ayushman Bharat Yojana, so taxpayers ultimately bear the inflated cost, and described the situation as a clear-cut case of fraud. One petition seeks directions to prevent unethical overpricing of essential medicines by pharmaceutical companies and retailers and strict enforcement of the Drugs (Prices Control) Order, 2013. The second petition seeks disciplinary action against registered medical practitioners who fail to prescribe generic medicines. Additional Solicitor General K. M. Nataraj, appearing for the India — India, said the government was not treating the matter as adversarial litigation and would place the existing mechanism before the court. The bench observed that price fixation is a major issue and posted the matter for further hearing on September 29, 2026. No final ruling has been issued.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard